论文信息 - Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension - 字舞流文

Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension

Lisa J. Martin | Ferhaan Ahmad | W. Chung | Yufeng Shen | S. Archer | R. Simms | R. Benza | D. Badesch | A. Frost | S. Nathan | C. Welch | M. Simon | Jiayao Wang | H. Farber | T. Lahm | E. Austin | R. Argula | T. Thenappan | N. Hill | R. Oudiz | R. Schilz | R. Frantz | F. Torres | T. Fortin | D. Ivy | W. Nichols | G. Elliott | R. Hirsch | M. Chakinala | A. Desai | E. Rosenzweig | R. White | J. Klinger | C. Burger | C. Barnett | J. Elwing | I. Robbins | M. Pauciulo | Hua He | Joseph M. Grimes | D. Yung | R. Benza | Z. Safdar | N. Zhu | K. Lutz | A. Coleman | N. Bhatt | J. Wilt | E. Austin | R. Walter | W. Nichols | S. Bakshi | Zia Rehman | C. Gonzaga‐Jauregui | Christopher Barnett | Ivan Robbins | V. Maddipati | M. Simon | Russel R. James Marc David Erika Charles Murali Thenappan Hirsch White Simon Badesch Rosenzweig Burg | Russel R. James Marc David Erika Charles Murali Thenappan Hirsch White Simon Badesch Rosenzweig Burg | R. White | Robert Simms | N. Hill | R. Walter

[1] Lisa J. Martin,et al. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis , 2018, bioRxiv.

[2] Justyna A. Karolak,et al. Complex Compound Inheritance of Lethal Lung Developmental Disorders Due to Disruption of the TBX-FGF Pathway. , 2019, American journal of human genetics.

[3] W. Chung,et al. Genetics and genomics of pulmonary arterial hypertension , 2019, European Respiratory Journal.

[4] Paul G. Williams,et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.

[5] L. Moreno,et al. miR‐1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries , 2018, The Journal of physiology.

[6] W. Chung,et al. Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension , 2018, Circulation. Genomic and precision medicine.

[7] Y. Courty,et al. Kallikrein-related peptidases in lung diseases , 2018, Biological chemistry.

[8] W. Chung,et al. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease , 2018, Genome Medicine.

[9] D. Fairweather,et al. Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease , 2018, Biology of Sex Differences.

[10] Henning Gall,et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension , 2018, Nature Communications.

[11] W. Chung,et al. Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults , 2018, Circulation. Genomic and precision medicine.

[12] D. Spandidos,et al. Genetically-modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)-based targeted therapy (Review) , 2018, International journal of molecular medicine.

[13] J. Paulus,et al. Racial and ethnic differences in pulmonary arterial hypertension , 2017, Pulmonary circulation.

[14] Jens Reeder,et al. Identifying and mitigating batch effects in whole genome sequencing data , 2017, BMC Bioinformatics.

[15] O. Vanakker,et al. GGCX-Associated Phenotypes: An Overview in Search of Genotype-Phenotype Correlations , 2017, International journal of molecular sciences.

[16] W. Chung,et al. The role of genetics in pulmonary arterial hypertension , 2017, The Journal of pathology.

[17] Trevor Hastie,et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.

[18] D. Conrad,et al. Genomewide significance testing of variation from single case exomes , 2016, Nature Genetics.

[19] Brent S. Pedersen,et al. Who’s Who? Detecting and Resolving Sample Anomalies in Human DNA Sequencing Studies with Peddy , 2016, bioRxiv.

[20] Stephen Kaptoge,et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis , 2016, The Lancet. Respiratory medicine.

[21] Stephan J Sanders,et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies , 2015, Science.

[22] M. Humbert,et al. Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects , 2015, Human mutation.

[23] W. Chung,et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society , 2015, Circulation.

[24] Kali T. Witherspoon,et al. Excess of rare, inherited truncating mutations in autism , 2015, Nature Genetics.

[25] W. Chung,et al. Genetics of pulmonary hypertension , 2014, Current opinion in cardiology.

[26] S. Archer,et al. The Right Ventricle in Pulmonary Arterial Hypertension: Disorders of Metabolism, Angiogenesis and Adrenergic Signaling in Right Ventricular Failure , 2014, Circulation research.

[27] W. Chung,et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. , 2014, Chest.

[28] M. Daly,et al. Searching for missing heritability: Designing rare variant association studies , 2014, Proceedings of the National Academy of Sciences.

[29] M. Humbert,et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension , 2013, Nature Genetics.

[30] J. Lumens,et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. , 2013, Journal of the American College of Cardiology.

[31] Huqun,et al. Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension , 2013, Respirology.

[32] Mauricio O. Carneiro,et al. From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[33] W. Chung,et al. A novel channelopathy in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[34] E. Bongers,et al. TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension , 2013, Journal of Medical Genetics.

[35] R. Benza,et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.

[36] W. Chung,et al. Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension , 2012, Circulation. Cardiovascular genetics.

[37] Y. Furutani,et al. Missense mutations of the BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[38] Graham M Lord,et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension , 2011, Human mutation.

[39] E. Diamandis,et al. Kallikrein-related Peptidase 12 Hydrolyzes Matricellular Proteins of the CCN Family and Modifies Interactions of CCN1 and CCN5 with Growth Factors* , 2011, The Journal of Biological Chemistry.

[40] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[41] MarcHumbert,et al. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010 .

[42] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[43] Shamil R Sunyaev,et al. Pooled association tests for rare variants in exon-resequencing studies. , 2010, American journal of human genetics.

[44] R. Durbin,et al. Mapping Quality Scores Mapping Short Dna Sequencing Reads and Calling Variants Using P

[45] E. Diamandis,et al. Distribution of 15 human kallikreins in tissues and biological fluids. , 2007, Clinical chemistry.

[46] R. Westrick,et al. Fatal hemorrhage in mice lacking γ-glutamyl carboxylase , 2007 .

[47] S. El-Dahr,et al. Mechanisms of Disease: the tissue kallikrein–kinin system in hypertension and vascular remodeling , 2007, Nature Clinical Practice Nephrology.

[48] R. Westrick,et al. Fatal hemorrhage in mice lacking gamma-glutamyl carboxylase. , 2007, Blood.

[49] A. Bissery,et al. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. , 2005, The Journal of clinical investigation.

[50] T. Morisaki,et al. BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension , 2004, Human mutation.

[51] S. Hunt,et al. Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. , 2002, Journal of the American Society of Nephrology : JASN.

[52] J. Ménard,et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53] M. Humbert,et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. , 2001, American journal of human genetics.

[54] S. Hodge,et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[55] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.